Last Updated: November 16, 2026

Details for Patent: 8,859,610

« Back to Dashboard


Which drugs does patent 8,859,610 protect, and when does it expire?

Patent 8,859,610 protects QBREXZA and is included in one NDA.

This patent has twenty-nine patent family members in thirteen countries.

Summary for Patent: 8,859,610
Title:Crystalline glycopyrrolate tosylate
Abstract:Salts of glycopyrrolate, including solid forms thereof are herein disclosed. Methods of making glycopyrrolate salts and methods of treating hyperhidrosis with salts of glycopyrrolate are disclosed.
Inventor(s):John Allan STATLER, Anthony Adrian SHAW, Delphine Caroline Imbert, Jennifer Leigh NELSON, Patricia Andres, Lisa Lynn McQueen, Stephan Xander Mattheus BOERRIGTER
Assignee: Aptuit LLC , Journey Medical Corp
Application Number:US14/024,484
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,859,610
Patent Claim Types:
see list of patent claims
Use; Formulation; Dosage form;
Patent landscape, scope, and claims:

US Patent 8,859,610: Scope, Claims, Expiration, and Glycopyrronium Tosylate Patent Landscape

US Patent 8,859,610 protects topical pharmaceutical solutions containing racemic glycopyrronium tosylate, including administration for hyperhidrosis and delivery through an absorbent pad. Its commercial relevance is tied to Qbrexza, the glycopyrronium tosylate topical cloth approved by the FDA for primary axillary hyperhidrosis. The patent does not claim glycopyrronium tosylate as a compound. It claims specified topical compositions, absorbent-pad presentations, and methods of treating hyperhidrosis.

The patent was issued October 14, 2014, to Dermira, Inc. Its earliest identified priority date is March 31, 2011. The standard patent-term endpoint is March 31, 2031, before any applicable patent-term adjustment or terminal-disclaimer effects. The patent is within the commercial exclusivity period for Qbrexza’s topical delivery technology. [1,2]

What drug and active ingredient does US Patent 8,859,610 cover?

The claimed active ingredient is glycopyrronium tosylate, also known as glycopyrrolate tosylate or glycopyrronium p-toluenesulfonate.

The claims describe the substance through its two stereochemical components:

  • (R)-3-((S)-2-cyclopentyl-2-hydroxy-2-phenylacetoxy)-1,1-dimethylpyrrolidinium 4-methylbenzenesulfonate
  • (S)-3-((R)-2-cyclopentyl-2-hydroxy-2-phenylacetoxy)-1,1-dimethylpyrrolidinium 4-methylbenzenesulfonate

The claimed composition must contain a racemic mixture of those two forms, or a solvate.

Patent element Scope
Active pharmaceutical ingredient Glycopyrronium tosylate
Stereochemical form Racemic mixture of the specified enantiomeric salts
Salt counterion 4-methylbenzenesulfonate, commonly called tosylate
Dosage form Pharmaceutically acceptable solution
Delivery form Topical administration; absorbent pad in certain claims
Primary indication Hyperhidrosis
Specified body sites Axilla, hands, feet, groin, face, back, and abdomen
Express additive Ethanol
Patent holder at issuance Dermira, Inc.
Patent number US 8,859,610 B2
Issue date October 14, 2014
Estimated standard expiration March 31, 2031

What are the independent claims in US 8,859,610?

Claims 1, 2, and 3 are the principal independent claims.

Claim 1: absorbent pad

Claim 1 covers an absorbent pad containing an absorbed pharmaceutically acceptable solution of racemic glycopyrronium tosylate, or a solvate, together with one or more pharmaceutically acceptable additives.

This is a product claim directed to a delivery article rather than merely to a liquid formulation. A wipe, cloth, swab, sponge, or comparable absorbent article may fall within the claim if it contains the required solution and the remaining claim elements are met.

The claim does not expressly require:

  • A particular concentration
  • A particular pad material
  • A particular pad size
  • A particular volume of solution
  • A particular drying state
  • A particular package
  • A particular administration site

The required features are the absorbent pad, the solution, the racemic glycopyrronium tosylate or solvate, and at least one pharmaceutically acceptable additive.

Claim 2: topical solution

Claim 2 covers a pharmaceutically acceptable solution of the racemic salt mixture or a solvate, with one or more pharmaceutically acceptable additives, for topical administration.

This claim is broader than the pad claims because it does not require an absorbent pad. A bottle, pump, dropper, applicator, spray, or other topical solution container could potentially fall within the claim if the formulation and intended topical use satisfy the limitations.

The claim does not expressly require treatment of hyperhidrosis. That limitation appears in claim 3.

Claim 3: method of treating hyperhidrosis

Claim 3 covers topically administering a therapeutically effective amount of the claimed solution to mammalian skin to treat hyperhidrosis.

The method requires:

  1. The claimed racemic glycopyrronium tosylate or solvate.
  2. A pharmaceutically acceptable solution.
  3. Topical administration.
  4. Administration to the skin.
  5. A therapeutically effective amount.
  6. Treatment of hyperhidrosis.

The method is not limited to humans until claim 4. Claim 4 narrows the method to a human patient.

How do claims 4 through 14 narrow the patent scope?

Claims 4 through 14 create a series of dependent method claims.

Claim Added limitation
4 The mammal is a human
5 Application to the axilla
6 Application to the hands
7 Application to the feet
8 Application to the groin, face, back, or abdomen
9 Administration with an absorbent pad
10 Human administration with an absorbent pad
11 Axillary administration with an absorbent pad
12 Hand administration with an absorbent pad
13 Foot administration with an absorbent pad
14 Groin, face, back, or abdominal administration with an absorbent pad

Claims 11 through 14 are commercially important because they combine the therapeutic method with both a body site and an absorbent pad.

For Qbrexza, the strongest direct overlap is likely with:

  • Claim 1, because Qbrexza is supplied as a medicated cloth.
  • Claim 2, because the cloth contains a topical solution.
  • Claim 3, because the product is used to treat hyperhidrosis.
  • Claim 4, because the approved indication is for humans.
  • Claim 5, because the FDA-approved indication is primary axillary hyperhidrosis.
  • Claim 10 or 11, because Qbrexza uses a cloth for human axillary administration.

What do claims 15 through 28 protect?

Claims 15 through 28 add ethanol as an express pharmaceutically acceptable additive.

They track claims 1 through 14 and require that ethanol be present in the claimed solution. These claims create narrower fallback positions if a broader composition or method claim is challenged.

The ethanol claims are commercially relevant because the Qbrexza product contains ethanol as part of its topical formulation. The claims do not, on their face, require a particular ethanol concentration. They also do not expressly limit the formulation to ethanol as the only solvent or additive.

The dependent-claim structure is unusually broad in geographic and delivery coverage:

  • General topical solution
  • Human treatment
  • Axillary treatment
  • Hand treatment
  • Foot treatment
  • Treatment of other listed body sites
  • Absorbent-pad delivery
  • Ethanol-containing versions of each category

What formulation characteristics are protected?

The patent’s formulation protection is centered on a solution containing racemic glycopyrronium tosylate and at least one pharmaceutically acceptable additive.

The claims do not expressly specify:

  • Glycopyrronium tosylate concentration
  • pH
  • Osmolality
  • Viscosity
  • Preservative system
  • Water content
  • Ethanol concentration
  • Drying characteristics
  • Packaging configuration
  • Pad loading
  • Application volume
  • Dosing frequency

That creates both breadth and litigation risk. Broad composition claims can reach multiple commercial formulations, but their validity may depend on written-description, enablement, anticipation, and obviousness analysis across the full scope of the claimed solution.

How does the patent treat a solvate?

The claims expressly include “a solvate thereof.” This language potentially reaches solvated forms of the racemic glycopyrronium tosylate, subject to the ordinary requirements of claim construction and proof of the relevant solid or solution state.

A product using a hydrate, alcohol solvate, or other characterized solvate could therefore face claim exposure if the product otherwise satisfies the solution and topical-use limitations.

Does US 8,859,610 claim the active ingredient itself?

No. The claims supplied do not claim glycopyrronium tosylate as a standalone chemical compound.

The patent claims:

  • A solution containing the specified racemic salt mixture.
  • An absorbent pad containing that solution.
  • Topical treatment of hyperhidrosis using that solution.
  • Ethanol-containing versions of those products and methods.

A competing product containing the same active ingredient could avoid this patent only if it falls outside the relevant composition, delivery, or method limitations. For example, changing the administration route from topical to oral would generally remove the product from the topical composition and method claims, although other patents could apply. Switching from a solution to a genuinely different dosage form could also matter, but the technical characterization would be fact-specific.

What is the FDA status of the related product?

Qbrexza is the primary marketed product associated with the patent technology. It is a topical glycopyrronium tosylate cloth approved under FDA NDA 210361 for primary axillary hyperhidrosis in adults and pediatric patients age nine years and older. The FDA approved Qbrexza on June 29, 2018. [3]

Regulatory item Data
Product Qbrexza
Active ingredient Glycopyrronium tosylate
Dosage form Topical medicated cloth
Strength 2.4% glycopyrronium tosylate
FDA application NDA 210361
Indication Primary axillary hyperhidrosis
Pediatric population Patients age 9 years and older
Original applicant Dermira, Inc.
Current commercial rights Associated with Incyte following its acquisition of Dermira

Qbrexza’s approved label directs application to each underarm using a single cloth. The label also warns against application to broken skin and contact with the eyes. Those labeling details are relevant to method-of-use and induced-infringement analysis but do not alter the literal scope of the patent claims. [3]

What is the Orange Book status of US 8,859,610?

US 8,859,610 is associated with the Qbrexza patent estate and has been identified in public drug-patent records as an Orange Book-listed patent for the product. Orange Book listing is important because it can trigger the Hatch-Waxman patent-certification framework for an ANDA applicant. [4]

An ANDA applicant seeking approval for a generic equivalent may need to submit:

  • Paragraph I certification if no patent information is listed.
  • Paragraph II certification if the listed patent has expired.
  • Paragraph III certification accepting delayed approval until expiration.
  • Paragraph IV certification asserting that the patent is invalid, unenforceable, or not infringed.

A Paragraph IV certification can create litigation risk for the applicant and may trigger a 30-month stay of approval if the patent holder files suit within the statutory period. [5]

The patent claims are particularly relevant to a generic cloth or wipe that uses:

  • Glycopyrronium tosylate
  • A topical solution
  • An absorbent article
  • Treatment of axillary hyperhidrosis
  • Ethanol as an additive

Are there Paragraph IV challenges or generic litigation?

The patent number alone does not establish a Paragraph IV filing, a notice letter, or a filed infringement action. A Paragraph IV challenge is an ANDA applicant’s statutory certification and is not created by the existence of a patent or an Orange Book listing.

Publicly available regulatory and court records should be evaluated separately for:

  • ANDA filing activity
  • Paragraph IV notice letters
  • District-court litigation
  • Delaware or other venue-specific complaints
  • Claim-construction orders
  • Inter partes review petitions
  • Settlements or license agreements
  • Authorized-generic arrangements

The supplied claim set contains no settlement terms, license terms, litigation judgment, or validity ruling. It therefore provides no basis for concluding that the patent has been invalidated, narrowed, or licensed to a generic competitor.

How strong is the patent estate for Qbrexza?

US 8,859,610 has meaningful commercial coverage because it combines three claim categories:

  1. Topical solution claims.
  2. Absorbent-pad claims.
  3. Hyperhidrosis treatment claims.

That combination creates multiple infringement theories around a Qbrexza-type product. A competing topical cloth could face product claims even before considering the method claims. A topical solution sold in a bottle could avoid the pad claims but remain exposed to the solution claims. A product marketed for hyperhidrosis could face method claims if it is used according to the patented treatment protocol.

The principal weaknesses are claim-specific rather than commercial:

  • The patent does not claim the active ingredient as a compound.
  • The claims require a solution.
  • The claims require the specified racemic mixture.
  • Method claims require topical administration and hyperhidrosis treatment.
  • The claims may be vulnerable to prior-art arguments concerning known topical anticholinergic formulations or obviousness.
  • The breadth of “pharmaceutically acceptable additives” may invite written-description and enablement disputes.

The patent is stronger against a close Qbrexza substitute than against a materially different anticholinergic product, a non-solution dosage form, or a different active pharmaceutical ingredient.

How does US 8,859,610 compare with competing hyperhidrosis patents?

The relevant competitive patent landscape includes four categories.

Patent category Typical protected subject matter Relevance to US 8,859,610
Compound patents Glycopyrronium or related antimuscarinic compounds 8,859,610 is not primarily a compound patent
Formulation patents Solvent system, concentration, pH, stability, skin penetration 8,859,610 broadly claims the topical solution
Device or pad patents Cloth construction, loading, packaging, applicator design 8,859,610 claims the pad in functional terms
Method-of-use patents Treatment of axillary or other focal hyperhidrosis 8,859,610 claims topical treatment across multiple body sites

Competing products such as topical aluminum chloride, botulinum toxin products, oral anticholinergics, and energy-based devices operate under different patent profiles. A product that does not contain glycopyrronium tosylate will generally not fall within the active-ingredient limitation of US 8,859,610, although it may face separate patents.

Biosimilar risk is not material to this patent. Qbrexza is a small-molecule drug, not a biologic, and generic entry would proceed through an ANDA rather than a biosimilar application under the Public Health Service Act.

What generic launch scenarios exist?

Scenario 1: Generic topical cloth

This is the highest-overlap scenario. A generic cloth containing racemic glycopyrronium tosylate in solution could implicate claims 1, 3, 4, 5, 9, 10, 11, and the corresponding ethanol claims.

Scenario 2: Generic topical liquid

A bottle or pump formulation could avoid the absorbent-pad claims but remain exposed to claim 2 and the related topical-treatment claims.

Scenario 3: Non-ethanol formulation

Removing ethanol could avoid claims 15 through 28, but it would not necessarily avoid claims 1 through 14.

Scenario 4: Different glycopyrronium form

A product using a different salt, stereochemical composition, or non-solvated form could present a non-infringement position. The success of that position would depend on whether the product still contains the claimed racemic mixture or a covered solvate.

Scenario 5: Different active ingredient

A topical formulation using oxybutynin, sofpironium, aluminum chloride, or another active ingredient would generally avoid the active-ingredient limitation of this patent, although it would require a separate freedom-to-operate review.

What geographic coverage does the patent provide?

US 8,859,610 provides protection only in the United States. Corresponding international or foreign-family applications may protect related subject matter in other jurisdictions, but a US patent cannot be asserted against conduct occurring entirely outside the United States.

Foreign analysis requires separate review of:

  • National-phase applications
  • Granted foreign patents
  • Local claim amendments
  • Patent-term adjustments
  • Supplementary protection certificates
  • Opposition or post-grant proceedings
  • Local validity and infringement standards

The US patent’s commercial importance is greatest in the US market because Qbrexza received FDA approval there and the claims map directly to the US-approved cloth presentation.

What manufacturing and intellectual-property barriers remain?

A generic manufacturer must address more than the active ingredient. The principal barriers include:

  • Reproducing a stable glycopyrronium tosylate solution.
  • Achieving uniform loading across an absorbent cloth.
  • Controlling evaporation and solvent loss.
  • Maintaining dose uniformity through packaging and shelf life.
  • Demonstrating bioequivalence or the applicable FDA standard for a topical product.
  • Resolving Orange Book patent certifications.
  • Managing method-of-use labeling for hyperhidrosis.
  • Avoiding infringement of continuation patents or separate formulation patents.
  • Establishing freedom to operate for cloth materials, packaging, and manufacturing processes.

Manufacturing-process patents are not apparent from the claims supplied for US 8,859,610. The patent is directed principally to the composition, delivery article, and therapeutic use rather than a detailed synthesis or cloth-manufacturing process.

What is the commercial exposure from US 8,859,610?

The patent is commercially significant because the claims reach the core Qbrexza product architecture:

  • The same active pharmaceutical ingredient.
  • A topical solution.
  • An absorbent cloth.
  • Human treatment.
  • Axillary use.
  • Ethanol-containing embodiments.

Revenue exposure depends on the share of sales represented by the US Qbrexza franchise, the existence of continuation patents, generic filing activity, and the enforceability of the listed claims. Patent expiration alone does not determine the earliest generic launch date if other Orange Book-listed patents remain in force.

Key Takeaways

  • US 8,859,610 is a topical formulation, absorbent-pad, and hyperhidrosis method patent.
  • It covers racemic glycopyrronium tosylate or a covered solvate in a pharmaceutically acceptable solution.
  • Claims 1 and 2 protect product formulations; claim 3 protects topical hyperhidrosis treatment.
  • Claims 4 through 14 narrow the methods by patient type, body site, and absorbent-pad use.
  • Claims 15 through 28 add ethanol.
  • The patent does not claim glycopyrronium tosylate as a standalone chemical compound.
  • Qbrexza is the principal commercial product associated with the claimed technology.
  • The patent was issued October 14, 2014, and has an estimated standard expiration of March 31, 2031.
  • Generic risk is highest for a Qbrexza-style medicated cloth containing glycopyrronium tosylate in solution.
  • Biosimilar risk does not apply because Qbrexza is a small-molecule drug.
  • Orange Book certifications and any continuation patents must be reviewed before estimating the earliest legally available generic launch date.

FAQs About US Patent 8,859,610

Does US 8,859,610 cover Qbrexza?

Yes. The claims materially overlap with Qbrexza’s glycopyrronium tosylate topical cloth, particularly the absorbent-pad, topical-solution, human-treatment, and axillary-use claims.

Can a generic avoid US 8,859,610 by removing ethanol?

Removing ethanol could avoid the ethanol-dependent claims, but it would not necessarily avoid the broader claims that require only a pharmaceutically acceptable additive.

Does the patent cover treatment of palmar or plantar hyperhidrosis?

Claims 6 and 7 expressly recite application to the hands and feet. Those claims create additional method coverage beyond axillary treatment.

Is a topical spray necessarily outside the patent?

No. A spray could avoid the absorbent-pad claims, but a spray containing the claimed racemic glycopyrronium tosylate in a pharmaceutically acceptable topical solution could still implicate the solution and method claims.

Does patent expiration guarantee immediate generic Qbrexza entry?

No. Generic entry may also depend on other listed patents, regulatory requirements, Paragraph IV litigation, settlements, exclusivity periods, and the generic applicant’s ability to obtain FDA approval.

References

  1. United States Patent and Trademark Office. (2014). US Patent No. 8,859,610 B2, Topical formulations of glycopyrrolate.
  2. Google Patents. (n.d.). US8859610B2: Topical formulations of glycopyrrolate.
  3. U.S. Food and Drug Administration. (2018). Qbrexza (glycopyrronium) cloth, 2.4% prescribing information.
  4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.
  5. 21 U.S.C. § 355(j). Abbreviated applications for new drugs and patent certifications.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 8,859,610

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Journey QBREXZA glycopyrronium tosylate CLOTH;TOPICAL 210361-001 Jun 28, 2018 RX Yes Yes 8,859,610 ⤷  Start Trial Y TOPICAL TREATMENT OF PRIMARY AXILLARY HYPERHIDROSIS IN ADULTS AND PEDIATRIC PATIENTS 9 YEARS OF AGE AND OLDER ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,859,610

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2014223172 ⤷  Start Trial
Australia 2016269524 ⤷  Start Trial
Canada 2902795 ⤷  Start Trial
China 105026369 ⤷  Start Trial
European Patent Office 2961734 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.